Group 1: Financial Performance - The company's revenue in Q1 2025 decreased significantly due to weak market demand and intensified industry competition, particularly in the generic drug sector, which was impacted by national centralized procurement policies that compressed drug price margins [4][5][6]. - As of Q1 2025, the company's net assets were approximately 998 million, with a debt-to-asset ratio of 30.75%, indicating an overall optimization of the asset-liability structure [8]. Group 2: Innovation and R&D - The company is evaluating the need for further clinical phases for its new drug, the dexketoprofen patch, after completing Phase I clinical trials, with subsequent R&D remaining uncertain [2]. - The management is exploring the integration of artificial intelligence in pharmaceutical product innovation but has not yet established partnerships with AI companies in the industry [7]. Group 3: Shareholder and Dividend Information - Due to negative retained earnings in the consolidated and parent company financial statements for 2024, the company does not meet the conditions for cash dividends, as detailed in the special announcement on April 25, 2025 [3]. - The company has received the first installment of 30 million from the sale of its subsidiary, with the remaining payment expected by June 25, 2025 [2].

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江亚太药业股份有限公司 （以下简称"公司"）将参加由浙江证监局指导，浙江上市公司协会 主办，深圳市全景网络有限公司承办的 "2025 年浙江辖区上市公司 投资者网上集体接待日暨 2024 年度业绩说明会"，现将相关事项公告 如下： 证券代码：002370 证券简称：亚太药业 公告编号：2025-056 浙江亚太药业股份有限公司 关于参加 2025 年浙江辖区上市公司投资者网上集体接待日 活动暨 2024 年度业绩说明会的公告 浙江亚太药业股份有限公司 董 事 会 2025 年 5 月 8 日 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（https://rs.p5w.net），或关注微信公众号：全景财经，或下 载全景路演 APP,参与本次互动交流，活动时间为 2025 年 5 月 13 日 （周二）15:00-17:00。 届时公司总经理岑建维先生，董事会秘书徐炜先生，财务总监徐 景阳先生，独立董事吕海洲先生（如有特殊情况，参与人员会有调整） 将在线就公司 2 ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥64,550,537.91, a decrease of 42.73% compared to ¥112,712,517.95 in the same period last year[4] - The net loss attributable to shareholders was ¥7,803,212.71, representing a 160.25% increase in losses from ¥2,998,386.71 year-on-year[4] - Total operating revenue decreased to ¥64,550,537.91 from ¥112,712,517.95, representing a decline of approximately 42.6% year-over-year[19] - Net profit for the period was a loss of ¥7,803,212.71, compared to a loss of ¥2,998,386.71 in the previous period, indicating a worsening of approximately 160.0%[20] - Basic and diluted earnings per share were both -0.0105, compared to -0.0049 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities increased by 50.56% to ¥11,574,799.13, up from ¥7,687,843.33 in the previous year[9] - Operating cash flow for the current period is ¥11,574,799.13, an increase of 50.5% compared to ¥7,687,843.33 in the previous period[22] - Total cash inflow from operating activities is ¥55,181,607.33, down 26.1% from ¥74,641,811.47 in the previous period[22] - Cash outflow from operating activities decreased to ¥43,606,808.20, a reduction of 34.8% from ¥66,953,968.14 in the previous period[22] - Cash and cash equivalents increased by ¥43,164,490.53, contrasting with a decrease of -¥57,104,256.47 in the previous period[23] - The ending balance of cash and cash equivalents is ¥762,863,213.79, up from ¥663,138,268.39 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,441,050,141.05, reflecting a 2.80% increase from ¥1,401,768,368.44 at the end of the previous year[4] - The company’s total liabilities increased significantly, with other payables rising by 155.20% to ¥48,882,214.68, compared to ¥19,154,466.61 last year[7] - Total liabilities increased to ¥443,188,946.04 from ¥429,587,364.82, marking an increase of approximately 3.0%[18] - Non-current assets totaled ¥436,421,017.37, down from ¥446,607,979.12, a decrease of about 2.4%[18] - The company’s total current assets amounted to RMB 1,004,629,123.68, up from RMB 955,160,389.32[16] Investment and Financing Activities - The company experienced a 98.01% increase in receivables financing, reaching ¥32,410,018.25, compared to ¥16,367,501.71 last year[7] - The company’s investment activities generated a net cash flow of ¥31,836,191.41, a significant increase from a negative cash flow of ¥2,890,338 in the previous year, marking a 1201.47% change[9] - Cash received from the disposal of subsidiaries and other business units is ¥30,000,000.00[23] - Cash paid for the purchase of fixed assets and intangible assets is ¥417,454.00, down from ¥2,890,338.00 in the previous period[23] - The company plans to apply for a credit limit of up to RMB 150 million from Agricultural Bank of China and RMB 30 million from Ningbo Bank[15] Operational Efficiency and Cost Management - The company is focusing on improving operational efficiency and reducing costs in response to declining revenues[19] - Total operating costs decreased to ¥70,881,335.56 from ¥114,454,069.55, a reduction of about 38.0% year-over-year[19] - The company reported a significant increase in research and development expenses, totaling ¥2,114,765.79, compared to ¥4,643,430.60 in the previous period, a decrease of approximately 54.5%[19] - The company has frozen funds of RMB 12,076,000 due to a legal dispute, while other funds totaling RMB 398,540,300 have been transferred to operational accounts[13] - The company has completed the cancellation of several fundraising accounts, with only one account remaining frozen[13] Shareholder Information - The company has a total of 745,667,530 shares outstanding, with 209,173,074 shares converted from convertible bonds[13] - The first quarter report has not been audited[24]

浙江亚太药业股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局核准签发的关于注射用阿昔洛韦的《药品补充申请 批准通知书》，公司注射用阿昔洛韦通过仿制药质量和疗效一致性评 价，现将相关情况公告如下： 关于公司注射用阿昔洛韦通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、药品基本信息 证券代码：002370 证券简称：亚太药业 公告编号：2025-054 浙江亚太药业股份有限公司 二、药品的其他相关情况 注射用阿昔洛韦适用于：1、单纯疱疹病毒感染：用于免疫缺陷 者初发和复发性粘膜皮肤感染的治疗以及反复发作病例的预防，也用 于单纯疱疹性脑炎治疗；2、带状疱疹：用于免疫缺陷者严重带状疱 疹病人或免疫功能正常者弥散型带状疱疹的治疗；3、免疫缺陷者水 痘的治疗。 药品名称：注射用阿昔洛韦 剂型：注射剂 规格：0.25g 原药品批准文号：国药准字 H20043811 注册分类：化学药品 上市许可持有人：浙江亚太药业股份有限公司 生产企业：浙江亚太药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于 改革药品医 ...

Core Viewpoint - The company has successfully passed the consistency evaluation for its injectable Acyclovir, enhancing its product pipeline and market competitiveness while gaining experience for future evaluations [1] Group 1: Product Development - The injectable Acyclovir is indicated for the treatment of herpes simplex virus infections, shingles, and chickenpox in immunocompromised patients [1] - The approval of the consistency evaluation will enrich the company's product line [1] Group 2: Market Position - The successful evaluation is expected to improve the company's market competitiveness [1] - The experience gained from this evaluation will facilitate the consistency evaluation of other products in the future [1]

浙江亚太药业股份有限公司 中兴财光华审专字(2025)第 318006 号 Xichena District.Beijing.Chin 内部控制审计报告 中兴财光华审专字(2025)第318006号 浙江亚太药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了浙江亚太药业股份有限公司(以下简称"亚太药业公司")2024 年 12月 31 日 的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效 性是亚太药业公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 在内部控制审计过程中,我们注意到亚太药业公司的非财务报告内部控制 不存在重大缺陷。 (此页无正文) 中兴财光华会计师事务所 (特殊普通合伙) 中国·北京 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于 情况的变 ...

浙江亚太药业股份有限公司 中兴财光华审会字（2025）第 318026 号 | | 1 | | --- | --- | | œ | 5 V | | | | | 合并及公司资产负债表 | 1-2 | | --- | --- | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | ব | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-97 | " Zhongxingcai Guanghua Certified Public Acc ADD: A-24E Vanton Financial Center No.2 Fuchengmenwal Avenue, Xicheng District, Beijing, China PC-100037 审计报告 中兴财光华审会字(2025)第 318026号 浙江亚太药业股份有限公司全体股东: 一、审计意见 我们审计了浙江亚太药业股份有限公司(以下简称亚太药业公司)财务报 表,包括 2024年 12月 31日的合并及公司资产负债表,2024年度的合并及公司 利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财务报表附 注。 我们认为 ...

2024 年度募集资金存放与使用情况 鉴证报告 中兴财光华审专字(2025)第 318008 号 关于浙江亚太药业股份有限公司 目 录 关于浙江亚太药业股份有限公司 2024 年度募集资金 存放与使用情况鉴证报告 2024 年度募集资金存放与使用情况专项报告 1-14 ichena District Belling China 关于浙江亚太药业股份有限公司 2024 年度募集资金存放与使用情况 鉴证报告 中兴财光华审专字(2025)第 318008 号 在鉴证工作中,我们实施了包括核查会计记录等我们认为必要的程序。我们 相信，我们的鉴证工作为发表意见提供了合理的基础。 三、鉴证意见 我们认为,后附的募集资金专项报告在所有重大方面按照《上市公司监管指 引第 2 号 一 上 市 公司 募 集 资 金 管 理 和 使 用 的 监 管 要 求 ( 2022 年修订 ) 》 ( 证 监会公告〔2022〕15 号）、《深圳证券交易所上市公司自律监管指引第１号一 一主板上市公司规范运作（2023年12月修订）》及相关格式指南的规定编制， 反映了亚大药业公司 2024年度募集资金存放与使用情况。 四、对报告使用者和使用目的的 ...

关于浙江亚太药业股份有限公司 2024 年度营业收入 扣除事项的专项核查意见 中兴财光华审专字(2025)第 318009 号 = Zhonaxingcai Avenue Xichena District Beijing China 关于浙江亚太药业股份有限公司 2024 年度营业收入 扣除事项的专项核查意见 中兴财光华审专字(2025)第 318009 号 浙江亚太药业股份有限公司: 我们接受委托,对浙江亚太药业股份有限公司(以下简称亚太药业公司) 2024 年度财务报表进行审计,并出具了中兴财光华审会字(2025)第 318026 号审计报告。在此基础上,我们对亚太药业公司编制的《浙江亚太药业股份 有限公司 2024年度营业收入扣除情况表》(以下简称"营业收入扣除情况表") 进行了核查。 一、管理层的责任 目 录 关于浙江亚太药业股份有限公司 2024 年度营 业收入扣除事项的专项核查意见 浙江亚太药业股份有限公司 2024 年度营业收 入扣除情况表 我们认为,后附的营业收入扣除情况表在所有重大方面按照《深圳证券 交易所股票上市规则(2024年修订)》和《深圳证券交易所上市公司自律监管 指南第1号 -- ...